行情

CATB

CATB

Catabasis Pharms
NASDAQ

实时行情|Nasdaq Last Sale

4.410
+0.420
+10.53%
已收盘, 16:00 04/08 EDT
开盘
4.060
昨收
3.990
最高
4.500
最低
4.060
成交量
17.58万
成交额
--
52周最高
9.76
52周最低
2.740
市值
7,892.65万
市盈率(TTM)
-1.8716
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CATB价格均价为37.50,最高价位60.00,最低价为15.00。

EPS

CATB 新闻

更多
  • 美联储用紧急降息争取时间 同时着眼推出新工具
  • 新浪美股 · 31分钟前
  • 外盘头条:美联储纪要称维持零利率直至消化疫情打击
  • 新浪美股 · 51分钟前
  • 工作中使用WhatsApp?摩根大通解雇了这名高级交易员
  • 新浪美股 · 1小时前
  • 减产传言不断 标普在能源股推动下进入"技术性牛市"
  • 新浪美股 · 1小时前

所属板块

生物技术和医学研究
+3.08%
制药与医学研究
+2.83%

热门股票

代码
价格
涨跌幅

CATB 简况

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.
展开

微牛提供Catabasis Pharmaceuticals Inc(NASDAQ-CATB)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CATB股票新闻,以帮助您做出投资决策。